Memo Date: February 26th, 2025
From: Vice President of Supply Chain
To: All Company
Subject: 2025 Supply Chain Risk and Impact Assessment - Update
We have been working closely with our various vendors and partners to analyze the impact of tariffs and other ongoing disruptions within the Life Science Sector.
We know today that our industry will begin experiencing the impact of tariffs on imports on March 7th. Our discussions have been focused on mitigating the impact on our cost base, and with astounding resolve, our partners have agreed to accept some of the burden placed on the raw material.
Therefore, I am happy to report that we can maintain the current cost structure without impacting our end users. We have also taken steps to front-load inventory and raw materials in 2025, securing our cost structure and ensuring stock is available when needed.
While we may still experience small gaps in supply due to unforeseen demand, we feel that our supply interruption risk is very low.
Our 2025 pricing structure is well cemented in place, providing protection against unforeseen interruptions through 2025.
Our commitment to our customers remains unwavering; we are excited to announce the purchase of a new mold injection factory in Brewster, New York. This strategic investment will allow us to expand production capacity and create even more new and innovative products for our customers.
Our proactive approach and continued investment in the future have positioned us to support our customers' successful research well into 2025 and beyond. We are committed to ensuring a seamless supply chain and are ready to meet the needs of our valued customers.
Jason A Walker
Vice President of Supply Chain
CELLTREAT Scientific Products